Please assess the completion status of the following clinical trial:

Trial Title: Safety/Efficacy Study of Optimizing Ibuprofen Dosing to Achieve Higher PDA Closure Rates

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All neonates (0-29 days old) less than or equal to 33 post-menstrual age at time of PDA diagnosis requiring nasal CPAP or mechanical ventilation~* Echo confirmed PDA with a transductal diameter of 1.5 mm or greater and demonstrating a left-to-right shunt~* Signed informed consent~Exclusion Criteria:~* Presence of: ductal-dependent congenital heart disease, pulmonary hypertension,~* Active bleeding (including Grade 3 or 4 IVH)~* Platelet count \< 100,000~* Coagulopathy~* Suspected NEC~* Suspected perforation~* Creatinine \> 1.5~* Hyperbilirubinemia requiring exchange transfusion~* Hypotension requiring pressor support~* Life-threatening congenital malformation

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 29 Days
- Healthy Volunteers: f

Study Arms:
- Optimized Ibuprofen (Type: EXPERIMENTAL): None
- Standard Ibuprofen (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).